SCHEMBL4471863

SCHEMBL4471863

COc1cc2c(Oc3ccc(Nc4ccc(C(C)(C)C)cc4)cc3Cl)ccnc2cc1OCCN1CCC(O)CC1

nearest known ligand 0.70

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 13/20 0.70
CSF1R P07333 1/20 0.54
KDR P35968 4/20 0.54
PDGFRB P09619 1/20 0.54
KIT P10721 1/20 0.54
PDGFRA P16234 1/20 0.54
EGFR P00533 2/20 0.48
EPHA2 P29317 3/20 0.48
EPHB4 P54760 3/20 0.48
AXL P30530 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4470866 0.96 FGFR2 (0.67) FGFR2CSF1RKDRPDGFRBKIT
SCHEMBL4483827 0.93 FGFR2 (0.82) FGFR2CSF1RKDRPDGFRBKIT
SCHEMBL4482645 0.92 FGFR2 (0.74) FGFR2CSF1RKDRPDGFRBKIT
SCHEMBL4466953 0.91 FGFR2 (0.70) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4470009 0.90 FGFR2 (0.85) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4467168 0.89 FGFR2 (0.81) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4476978 0.89 FGFR2 (0.76) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4482481 0.88 FGFR2 (0.69) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4476070 0.88 FGFR2 (0.72) FGFR2CSF1RKDRPDGFRBKIT
SCHEMBL4464266 0.87 FGFR2 (0.69) FGFR2EGFRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885CSF1R 88/4885KDR 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.